Improving outcomes from pneumococcal meningitis (PM), particularly in populations with high HIV prevalence, requires better understanding of host inflammatory responses to infection.
Interpretation: These data suggest poor outcome in PM is associated with overexpression of IL-17 and T1-IFN associated pro-inflammatory responses in the CSF and suggest a role for neutrophil-mediated inflammation. These responses are unlikely to be effected by current adjunctive treatments. Improving poor outcomes from PM will require better-targeted interventions.
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Text Background
Streptococcus pneumoniae remains the most prevalent cause of community acquired meningitis-associated mortality and morbidity in adults in most settings. [1] [2] [3] The greatest burden of pneumococcal meningitis (PM) falls in low and middle income countries (LMICs) with high HIV prevalence. Estimates of incidence in adults and adolescents in these settings varies between 3-40/100 000, compared to 0.2-1.5/100 000 in high resource, low HIV prevalence settings. [4] [5] [6] [7] [8] In LMICs with high HIV prevalence, the reported mortality in adults and adolescents from PM is 50-70%. 9, 10 Animal model and human post-mortem studies indicate that disease pathogenesis in PM is characterised by a marked inflammatory response to bacterial invasion in the CSF, rather than an inability to mount an immune response. The inflammatory cascade and cytotoxic effects of host pro-inflammatory mediators 11, 12 together with bacterial toxins drive tissue damage characterised by apoptotic neuronal cell injury, raised intracranial pressure (ICP), thrombosis, cerebral oedema, and cerebral ischaemia. 13, 14 These findings supported the use of anti-inflammatory agents, such as dexamethasone as adjunct therapies for PM. Dexamethasone has demonstrated efficacy in controlled trials in industrialised countries in HIV-negative adults with PM, with an estimated relative risk reduction in mortality of 0.5 (95% CI 0.3 -0.83). 15 However, adjunctive dexamethasone and glycerol therapies have proven to be ineffective or even harmful in LMIC settings when tested in controlled trials, irrespective of HIV-1 serostatus. 2, 16, 17 The differences in in overall case fatality rates by geographical location and response to dexamethasone in patients with PM are unexplained. Patients with bacterial meningitis in LMICs are younger, have a higher incidence of HIV co-infection, present later, and have important differences in bedside predictors of poor outcome compared to patients in better resourced settings. 18, 19 HIV-1 co-infection is not associated with worse outcomes from PM in any setting. [18] [19] [20] Data from animal models and from patients from industrialised countries suggest excessive inflammatory responses determine disease severity, but this may not reflect the situation in LMICs.
Disease-specific immunomodulatory transcriptomic signatures have been identified that are strongly associated with disease severity and outcome in sepsis and influenza. [21] [22] [23] In contrast, published reports on the transcriptomic response in bacterial meningitis are limited to human brain-endothelial cell lines and animal models, 24, 25 data in human disease are lacking Based on our previously reported observation of a strong association between poor outcome and low CSF leukocyte counts in patients recruited to our centre, 19 we tested the hypothesis that neutrophil-specific transcriptional activity would be downregulated in both blood and CSF in non-survivors of PM compared to survivors.
We report the results of our investigation into the blood and CSF host transcriptomic responses in Malawian patients with S. pneumoniae meningitis on admission to hospital. We have used network analyses and cellular and process deconvolution of the blood and CSF transcriptome to identify important components of the host inflammatory response associated with poor outcomes from pneumococcal meningitis.
expression in the two compartments was examined using principal component analysis (PCA) . Samples from the CSF transcriptome clustered separately to those from the blood transcriptome (Figure 2A ), indicating important differences in gene expression between the two compartments. To investigate these differences, we ran all mapped genes expressed over 3 gene copies/million reads (CPM) in CSF and blood compartments through the clustering programme MIRU. Enriched gene clusters were tested against curated functional pathways compartments using InnateDB pathways over-representation analysis (ORA). The CSF compartment contained multiple gene clusters that were highly enriched for both innate and adaptive immune response pathways, damage repair and stress response, endothelial activation and synaptic neurotransmitter activity ( Table 2 ). In contrast, the blood compartment contained fewer enriched gene clusters that mapped to immune pathways, and relatively greater enrichment of cell cycle and protein synthesis genes as well as gene clusters for hormonal signalling and carbohydrate metabolism (Table   3 ). Gene clusters were also detected in blood that mapped to endothelial damage, extracellular membrane breakdown and proteoglycan synthesis ( Table 3) .
We then tested if gene expression within each compartment differed between outcome groups. Principal component analysis of CSF gene expression showed a complete separation of sample clusters between survivors and non-survivors ( Figure   2B ). 1678 genes were differentially expressed (FDR <0.05 Log Fold Change (LFC) >0.5) in the CSF compartment; (762 genes upregulated in non-survivor CSF and 916 genes in survivor CSF) ( Figure 1C ). In contrast, very few genes were differentially expressed between outcome groups in the blood compartment (7 genes upregulated in survivor blood and 18 in non-survivor blood) ( Figure 1D ). We undertook a network analysis using a gene networking software (XGR) to determine if the differentially expressed genes were interconnected. Differentially expressed genes in survivor CSF clustered around two central gene hubs. The first represents genes involved in DNA and cellular response to damage and transcriptional control, including hubs CCND1 and HIST2H4A. The second cluster represents genes involved in immunological signalling, including PIK3CD (multiple immunological signalling), DVL2 and FZD2 (Wnt signalling) and FCGR3A (Fc receptor for IgG) ( Figure 3A) . A further small gene cluster represented amino-acid metabolism. In comparison, genes enriched in the CSF from non-survivors clustered in a large central network of genes encoding pro-inflammatory mediators including IL-1B, TNF, IL-6, MMP9 and IGF-2 ( Figure 3B ). Peripheral clusters to this central network included genes involved in platelet aggregation, vasoconstriction and collagen breakdown, prostaglandin biosynthesis, cytoskeleton remodelling, and cell membrane synthesis ( Figure 3B ).
To test the veracity of our findings, we re-analysed the mapped CSF data using an alternative software programme Gene Set Enrichment Analysis (GSEA). We used this software to annotate all differentially expressed genes for both outcome groups with Gene Ontology (GO) functional terms. GO terms that were highly enriched in the GSEA annotation (FDR <0.05) included 'Positive regulation of reactive oxygen species', 'Extracellular matrix' and 'Granulocyte migration' in non-survivors. 'DNA replication', 'Damaged DNA binding' and 'G-protein coupled chemoattractant' were enriched in survivors, amongst others (Supplementary data 1).
To determine the transcriptional foot-print of both cell-specific gene expression and functional inflammatory processes, we compared the expression of transcriptional response-modules for specific white cell subsets and cytokines between survivors and non-survivors in CSF and blood, validated in patients in sub-Saharan Africa. 30, 31 The geometric mean expression of the neutrophil, monocyte, T-cell, TNF-and Type 2 interferon-response modules did not differ between survivors and non-survivors in the CSF transcriptome ( Figure 4 ). However, expression of IL-17, IL-10 and Type 1
Interferon gene response modules was significantly increased in the CSF of nonsurvivors compared to survivors ( Figure 4 ). No differences in cell or functional gene response-module expression between outcome groups were detected in the blood transcriptome, apart from increased expression of the monocyte response-module in survivors ( Supplementary Figure 1 ). Figure 2 ). To consolidate these findings, we then used the modular analytical approach to test the expression of genes from individual neutrophil-specific functional GO terms. We found enrichment of genes associated with neutrophil chemotaxis and apoptosis in non-survivor CSF, but no differences in expression of genes for either neutrophil degranulation or cytotoxicity ( Figure 5A , Supplementary data 2). Neutrophils expressing persistence or survival-associated genes CSF3 and NR4A3/1 have been associated with pro-inflammatory states in models of neutrophilic inflammation. 32, 33 To test for evidence of neutrophil survival/persistence, we examined individual expression of these genes. Expression of CSF3, NR4A3 and NR4A1 were all markedly enriched in non-survivor CSF ( Figure 5B ), suggesting the presence of a sub-population of neutrophils within the CSF expressing a strongly pro-inflammatory phenotype.
Interpretation
Why patients with PM in LMICs with high HIV-1 prevalence have worse clinical outcomes compared to better resourced settings remains poorly understood. Our transcriptional approach has identified the harmful host inflammatory pathways that characterise non-surviving adults with PM in Malawi, going some way towards explaining why interventions targeted on attenuating the inflammatory response have failed. Patients enrolled in our study were typical of PM adults in sub-Saharan Africa:
predominately young, HIV-1 co-infected, and presenting with profoundly low CSF neutrophil counts and very high bacterial loads. 1, 34 The differences in pro- The CSF bacterial load was higher in non-survivors compared to survivors in our study, presenting a potent stimulus for the upregulated T1-IFN and IL-17 driven proinflammatory cascade. 49, 50 We have previously shown in earlier, larger studies that persistence of pneumolysin in the CSF rather than absolute CSF bacterial load is more strongly associated with poor outcome in PM. 51, 52 Pneumolysin is a pneumococcal pore-forming toxin and possible TLR4 agonist, and is involved in IL-17 activation of the neutrophil NLRP3 inflammasome in models of pneumococcal infection. 53 Pneumolysin has been shown in PM to kill neutrophils, attenuate CNS leukocyte counts and cause direct neuronal cell death through synaptic dysfunction. 14, 54, 55 Our data show that the presence of increased pneumococci in the CSF is a significant driver of the observed CSF pro-inflammatory cascade, overexpression of the IL-17 pathway, attenuated neutrophil activity and increased host cell damage in may be due to correspondingly increased production of pneumolysin in the CSF. 56 High bacterial loads in the CSF of non-survivors in our study suggest bacterial control by neutrophils may be ineffective in these patients, we hypothesised that the neutrophil transcriptome would be down-regulated in non-survivors. Neutrophils are both the most abundant CSF cell type in PM, and a critical component of the innate host response to infection in bacterial meningitis. 12 Low CSF leukocyte counts are recognised as a poor prognostic factor in bacterial meningitis in all settings. 9, 19, 40 Interestingly, we observed increased CSF neutrophil chemotaxis signalling in the presence of the pro-inflammatory cascade in non-survivors, but we did not detect the expected increases in either CSF neutrophil count, neutrophil response module expression or gene expression for degranulation or phagocytosis that should follow from expression of these powerful migration signals. 57,58 However, we detected significant upregulation in non-survivors of genes coding for neutrophil persistence stages of the project. We would like to thank Professor Judith Breuer and the staff of the Pathogen Genomics Unit at University College London for their assistance with library preparation and RNA sequencing. The authors acknowledge the use of the UCL Legion High Performance Computing Facility (Legion@UCL), and associated support services, in the completion of this work. 
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